ASX-Dividend-Report-Banner

Alma Expands Injectables Presence in APAC with Profhilo® Launch in Thailand

December 12, 2024 12:00 PM AEDT | By Cision
 Alma Expands Injectables Presence in APAC with Profhilo® Launch in Thailand
Image source: Kalkine Media

CAESAREA, Israel, Dec. 12, 2024 /PRNewswire/ -- Alma Lasers, a Sisram Medical company and a global leader in energy-based medical and aesthetic solutions, announced today the opening of its new subsidiary in Thailand, alongside the launch of Profhilo®, a groundbreaking dermal bio-remodeler exclusively distributed by the company in Thailand.

Committed to delivering lasting results to Thai beauty seekers through clinical excellence and an exceptional patient journey, Alma launches the bio-remodeler Profhilo® in Thailand.
Committed to delivering lasting results to Thai beauty seekers through clinical excellence and an exceptional patient journey, Alma launches the bio-remodeler Profhilo® in Thailand.

Recently approved by the Thailand Food and Drug Administration (TFDA) for use on the face and neck, Profhilo® is indicated for remodeling laxity and supporting dermal tissue repair in cases of acne scars. Now available to Thai practitioners, it sets a new benchmark for high-quality aesthetic care for both doctors and patients.

The flagship Swiss-based bio-remodeler, Profhilo®, delivers a unique "beneath-the-skin" hyaluronic acid treatment, powered by patented NAHYCO® technology. This advanced formulation provides a prolonged stimulating effect on dermal cells, rejuvenating the skin by improving laxity, skin quality and restoring firmness.

Unlike traditional wrinkle treatments or dermal fillers, Profhilo® works by stimulating collagen and elastin production while deeply hydrating the skin, resulting in natural, long-lasting improvements in skin quality.

Alma's new Thailand office and the seventh Asia Pacific subsidiary, will serve as a strategic hub, supporting the company's growing presence in Southeast Asia—a region rapidly establishing itself as a global leader in aesthetics. Thailand, in particular, holds major potential as one of the most dynamic economies in the region and a thriving market for aesthetic treatments. The market value of the injectable segment in Thailand has also soared significantly, reaching an estimated 57 billion Thai Baht in recent years.

The Company is confident that this expansion into Thailand offers exciting long-term growth opportunities for its brand and business in the region and globally, by promoting the Company's comprehensive portfolio and innovative products such as high-end injectables and one-of-a-kind skin-care concepts.

The introduction of Profhilo® to the Thai market marks a significant milestone in Alma's expansion of its injectables business. Alma's comprehensive injectables global footprint includes distribution rights of Profhilo® in other APAC markets and Prollenium for its renowned dermal filler collection, FDA & CE approved Revanesse, in several key markets, including Germany, Austria, Switzerland, Australia, New Zealand, and United Kingdom, with potential expansion into other regions.

"Thailand is a strategic area for Alma to continue its leadership in the APAC market, and the introduction of Profhilo® showcases our commitment to bringing Thai beauty seekers lasting experiences through clinical excellence and an exceptional patient journey," said Lior Dayan, CEO of Sisram and Alma.

He continued, "The launch of Profhilo® represents a significant advancement in our offerings, providing consumers with a deeply hydrating skin solution, resulting in natural and long-lasting improvements in skin quality. Alma will continue to enhance our diversified product portfolio, reinforcing our mission to improve patients' quality of life and prioritize the customer journey as a key driver of our long-term success."

Mr. Alon Tzionit, President of Alma Thailand, stated: "The global aesthetics market today demands excellence in quality, safety, and natural results. In Thailand, we have observed that patients are increasingly seeking skin treatments that deliver sustainable improvements with minimal downtime, while also ensuring ease of application for medical professionals."

He added, "Profhilo® stands out as the ideal innovation to meet these needs. With its unique NAHYCO Hybrid technology, designed to stimulate collagen, elastin, fibroblasts, keratinocytes, and adipocytes while deeply hydrating the skin, we are confident that this bio-remodeler will become a cornerstone treatment in aesthetic clinics nationwide"

About Alma:
Alma is a world-leading innovator and provider in the aesthetic and surgical markets, offering holistic cutting-edge solutions such as Laser, Light-based RF, and Ultrasound technologies. We enable practitioners to deliver safe, effective and life-transforming treatments to their patients, utilizing state-of-the-art and clinically proven solutions. For more than two decades, Alma's multiple award-winning products have established a new benchmark in the medical aesthetic industry, both in terms of clinical excellence and innovative breakthrough.

Logo - https://mma.prnasia.com/media2/2047372/Alma_Logo.jpg?p=medium600
Photo - https://mma.prnasia.com/media2/2573665/Alma_APAC.jpg?p=medium600

For media inquiries, please contact
Alma PR team
[email protected]


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.